TRIS: a mobile app with breathalyzer to support sobriety in alcohol use disorder
Official title: Remote Treatment With Incentives for Sobriety (TRIS): A Randomized Controlled Trial of a Contingency Management App for Alcohol Use Disorder
Run by University of Sao Paulo General Hospital · NCT07735585 · Data updated 2026-11-12
A smartphone app with a connected breathalyzer tests for abstinence and uses small financial incentives to encourage sobriety for adults with AUD in Brazil.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | University of Sao Paulo General Hospital Academic / other |
| Locations | 1 site (São Paulo, São Paulo) |
| Status | Recruiting |
| Started | February 19, 2026 |
| Main results expected | August 2027 |
| Study ends | December 2027 |
| Registry record updated | July 30, 2026 |
| Trial ID | NCT07735585 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 with a current AUD diagnosis, seeking treatment at AME Vila Maria or Instituto Perdizes in São Paulo, able to use a smartphone and read Portuguese, with BrAC 0.00 at consent.
✕Probably not a fit
Individuals who do not respond to contingency incentives or who have safety concerns or unreliable access to a smartphone may see little benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial tests whether adding TRIS, a Brazilian mobile app integrated with a Bluetooth breathalyzer, to standard outpatient care increases days of verified abstinence from alcohol. Participants are randomized to receive 12 weeks of remote contingency management via TRIS plus usual care or usual care with remote monitoring but no incentives. Daily BrAC samples are submitted through the app, and incentives are provided only when all three daily samples are alcohol-negative and on time. The study enrolls 130 adults with AUD from two public clinics in São Paulo and uses a 1:1 randomization. Primary outcome is the number of biochemically verified abstinent days during the 12-week period; secondary outcomes include patterns of use, adherence, usability, withdrawal, craving, and related symptoms.
Why it matters
Potential benefit: If successful, TRIS-based contingency management could help more patients maintain abstinence and improve engagement in treatment.
How similar studies have gone: Contingency management approaches for AUD have shown benefit in prior research, supporting exploration of a remote, app-based delivery.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able to read and speak Portuguese. * Provide signed informed consent. * Age 18 to 70 years. * Alcohol consumption within the past month. * Current diagnosis of Alcohol Use Disorder (AUD). * Seeking treatment for AUD at AME Vila Maria or Instituto Perdizes. * Breath alcohol concentration (BrAC) of 0.00 at the time of consent. * Own and be able to operate a smartphone with an active mobile service plan. * Smartphone compatible with the Bluetooth frequency required for the BACtrack breathalyzer. Exclusion Criteria: * Crack cocaine use within the past 90 days. * Any seizure episode within the past 12 months. * Diagnosis of a psychotic disorder (DSM-5). * Suicide attempt within the past two years. * Any medical or psychiatric condition that may compromise safe participation, as determined by the study medical director.
Where it's running
-
IPER Research Center
São Paulo, São Paulo, Brazil Recruiting
Study contacts
- Principal investigator: André Miguel, PhD — Washington State University
- Study coordinator: Vinicius Soares, PhD
- Email: viniciusnagy@gmail.com
- Phone: +55 19 99586-4530
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder
This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.
-
Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD
A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.
-
Do beverage cues drive craving in adults with AUD
In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.
-
Semaglutide for Alcohol Use Disorder and Obesity: Testing 1.0 mg and 2.0 mg vs Placebo
We’re testing two doses of semaglutide to see if they reduce alcohol craving and use in adults with alcohol use disorder and obesity compared with placebo.
-
Body-focused mindfulness added to inpatient alcohol use disorder treatment
This trial tests whether a body-focused mindfulness program can help people with alcohol use disorder feel more connected to their bodies and reduce cravings while in inpatient care.
-
Optimizing Smart Messaging for Alcohol Recovery
A smartphone-based program tests whether tailored recovery messages can help people with alcohol use disorder stay engaged with support resources and improve health outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.